Rebel
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ummmmm...no.
Not an excuse. It's just what happened. Everyone wants to see them become current again and that WILL happen, but in the meantime you should focus on the BIG PICTURE because it's much DEEPER than just the financials.
As you well know, things changed with regard to the financials, from filing in dribbles to wham bang all at once. So give him a break. He was just making optimistic assumptions and predictions that turned out to be off.
The entire matter of financials is out of his hands and he is most likely going along with whatever advice he is receiving from RRBB and the ARYC attorneys and whomever else may be involved, like the SEC.
The proof will come when the time is right, and if you don't believe him, then you should move on.
Wrong again. Guidance was $2 million billed in a week, not $1 million. "Guidance" is actually an official prediction based on what Dr. Schena knows. He wouldn't throw that out publicly if it weren't true.
So sorry, Pug. My sympathy goes out to you and your family. It would be a wonderful thing if we could keep our moms with us our entire lives. I think your mom is now playing piano with the angels...
Yes sir, and we have surpassed 10-day average volume by about 1 million, and it's only 12:15.
Awesome day.
lol. Is that all you've got? The big 3? How original!
I think this MUST be United HealthCare: Wow!
(20 minutes ago) Arrayit clinical sales team reports doctor-ordered allergy testing services sale to a top health benefits company headquartered in the United States and providing premium healthcare coverage to 50 million+ Americans on annual revenues topping $200 billion http://arrayit.com/Clinical/Allergy_Test/allergy_test.html …
https://twitter.com/arrayit?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor
DJ Sorrento Therapeutics (SRNE) Price Target Raised to $12.00/Share From $10.50 by B. Riley - 11:25 AM ET 3/20/19 | Dow Jones
Other analysts are saying $20's or more.
https://www.tipranks.com/stocks/srne/price-target
It's sad and depressing when the ARYC share price rises or if the sun is shining or if he wins the lottery or if the world finally achieves world peace and harmony.
It's all stinky and bad.
To the moon of course.
:)
Amazon started at $18 and is now going for $1,800.00. As a company builds itself up and grows, so does the share price (duh).
But I think you know that.
lol
Good grief. Look who's talking about panic!
Too funny.
You're on a roll today with your abysmally incorrect statements. No, you may not have even one of my shares.
You sound a bit ANXIOUS, depressed and sad. Just buy at the ask and all will be well.
I see that is one of your favorite words, "babbling." It's a good one all right, but certainly does NOT describe Dr. Schena.
You snooze you lose. Of course, if you HATE ARYC, there are a gazillion others out there for you. So good luck and adios.
Just buy at the ask. It won't kill you.
Duh. Good news usually causes a stock to rise in price, but thanks for the reminder.
lolol.
Who cares. I hereby declare this stock is not overbought. That is an ABYSMAL and INCORRECT statement in the case of ARYC.
No, that is NOT ALL that matters. Look a little deeper while you wait for the financials to come through.
:)
Duh. That's why the stock is so cheap. Sometimes you have to just believe, which isn't hard at all if you have done your homework and know the TRUE FACTS surrounding ARYC and its PROVEN technology, customers, partners, patents, portals, etc.
Nice going, Mr. Steamer! I think many wealthy people will be created right here with a little time and patience. Congrats and best of luck to you and all the good people on this board!
VYST
:))
Wow, nice going SRNE. This move north has been a long time coming! Still way, way undervalued.
Haven't you heard about the BUYBACK of shares, which shares will be retired and returned to the treasury??? What difference does it make what the CURRENT OS is anyway? It's going to CHANGE for the better, and that's enough for me.
Duh. Yes everyone deserves to know, but the companies are in a state of flux right now due to audits, consolidation of the companies and their balance sheets. It's all good and all will be revealed upon completion. They are paying off debt, not diluting! Imagine the poor TA having to answer gazillions of phone calls from crazy people when things are still in a state of transition.
Patience is a virtue here. There's a lot to do. Now have a cookie and relax.
Repeat, repeat, repeat...preditable, meaningless hysteria that adds nothing to this clambake.
It's mentioned here on Arrayit's Facebook? Arrayit Corporation - ARYC
October 15, 2015 · As printed in GenomeWeb this morning, see story below. Some time back we publicly challenged Theranos to a miniaturization challenge, who can do more testing with a finger stick of blood? Answer...Arrayit. We openly do demonstrations on how our patented technology works and know very well it's strengths and limitations.
Just a Pinprick
Oct 15, 2015
Theranos, the company started by Elizabeth Holmes, isn't using its own technology for many of the tests it runs, the Wall Street Journal reports.
The $9 billion-valued company has been hailed for its development of a low-cost testing approach that only requires a tiny amount of blood and has a fast turn-around. But four former employees have told the Journal that the company only uses its Edison device for a fraction of the 240 tests it offers — one former senior employee placed it at 15 tests as of December 2014. Further, the Journal says the workers weren't confident in the results given by the platform.
In addition, according to the former senior employee, Theranos uses a special dilution method for about 60 of the tests it runs on other companies' platforms — since the company collects such small amounts of blood, it has to bring the sample volume up to what those machines require, the Journal says. For other tests, the company collects larger amounts of blood.
The Journal also reports potential irregularities in proficiency testing at Theranos. By reviewing company emails, it found that Theranos split samples sent to it for testing, running half on its Edison platform and half on machines from other companies. The two gave differing vitamin D, thyroid hormone, and prostate cancer testing results, suggesting to some workers that the Edison results weren't right, the WSJ says.
It adds that the company only sent back the non-Edison results, which it says could violate testing rules as proficiency testing samples are supposed to be handle just like patient samples, and at that time, Edison was used for such tests according to the former employees.
Some doctors have stopped sending patients for Theranos testing, the WSJ reports. In one instance, a patient with ringing in her ear went for testing, and her results showed abnormally high levels of glucose, calcium, total protein, and three liver enzymes. Her doctor, worried about a stroke, sent her to the emergency room. Tests there, the Journal notes, showed nothing abnormal.
Theranos tells the WSJ that its methods for preparing samples for analysis are trade secrets, though their methods have been disclosed to regulators. In addition, the company says it has no indication that any inaccurate results have been returned to patients and that it has disclosed that it runs "certain esoteric and less commonly ordered tests" on other machines. It adds that its lab work is accurate.
https://www.facebook.com/Arrayit/posts/as-printed-in-genomeweb-this-morning-see-story-below-some-time-back-we-publicly-/10153825081392259/
Perfect! ASCK Auscrete Corporation Announces Uplisting to OTCQB 8:00 AM ET 3/15/19 | GlobeNewswire
ASCK Auscrete Corporation Announces Uplisting to OTCQB Market
GOLDENDALE, Wash., March 15, 2019 (GLOBE NEWSWIRE) -- Auscrete Corporation (OTCQB: ASCK) (the "Company"), which custom designs specialty Concrete Affordable Housing and Manufacturers of Building Products, today announced that its common shares have been approved for trading on the OTCQB Marketplace (OTCQB) under the symbol "ASCK" effective as of the open of trading yesterday.
"The listing of our common stock to the OTCQB Exchange is an exciting milestone for Auscrete Corporation," said John Sprovieri, President of Auscrete. "While ASCK has been a fully reporting company since its inception, and we always hold ourselves to the highest regulatory and compliance standards, we believe that the broader exposure afforded by the OTCQB will raise our visibility within the investment community and assist in increasing the liquidity of our common stock. In addition, we believe that trading on this established public market will help to generate exposure of our Company among institutional investors."
Mr. Sprovieri added, "even though 2018 turned out to be a somewhat disappointing year with a financing contract being scarcely supported, we came up short on total financing and had to look elsewhere. We were able to initiate the first steps with the minimal financing we received and expect to break ground in a few weeks for construction of our new Production Building on our land in Goldendale, WA."
About Auscrete Corporation
Auscrete is a manufacturer of concrete-based building materials for construction of affordable housing. We are developers of specialty hybrid concrete insulated building components that are energy efficient, super strong and require very low maintenance.
Lee Odom, the IR Director, was quoted as saying, "this uplist will definitely change the zip code for the Company, this looks to make for an exciting year ahead for ASCK as the housing market is critically in need of our products. Studies continuously show low cost housing to be one of the scarcest & most over-looked commodities on the globe today."
Mr. Odom also added, "Auscrete Corporation provides building materials to contractors and developers, for the construction of their thermally efficient and structurally superior 'Affordable Housing.'"
Uptick Newswire will interview ASCK's President on the Stock Day Podcast next week to discuss the Future Direction and Projections for Auscrete.
This interview will be available for listeners Tuesday, March 19(th) at 9:00 am ET. Please visit Uptick Newswire's website https://upticknewswire.com/ to hear the entire interview.
Yep, and we have the official Father of Microarrays as our President. Good times ahead.
"The Scientist places Dr. Schena at positions 1 and 2 on the “microarray family tree”, confirming his role as the founder of microarray technology and substantiating his Father of Microarray Technology status. More than 100,000 laboratories in 50 countries are using microarrays to explore basic questions in biology, chemistry, agriculture and medicine, and the proliferation of the technology has resulted in 797,000 microarray publications since Dr. Schena’s original 95’ Science paper."
That is like the creepiest looking thing ever. Wish I could un-see it.
Absolutely incredible. Thanks for your hard work in keeping on top of these enrollments.
And some here remember the .0004's. Seems incredible, doesn't it? Good fortune to you!
Oops.
You're welcome.
:))
Great day for SCYX. Can you believe the share price was in the $.30's and $.40's at the end of December? So ridiculously undervalued.
That can't last forever. They will do what they do, but longs are eating up gazillions of shares at bargain prices so a lockdown of the float could be close.
Fantastic is putting it mildly. Wow and thank you. My insane buying frenzy is going to pay off quite nicely. Not selling one share for a very, very long time. The Rotmans are upstanding people with integrity rarely seen down here in the valley of pinkies.
What an awesome, get-in-early opportunity this is...VYST.
PLUS, ARYC retained the exclusive right to manufacture OvaDx.
Nice video, thank you. The bulls are in control. It does look that way.
Yippee!
Thank you for sharing this. It's all good. Just gonna keep buying and laughing at the absurdity.